|
April 23, 2010
Press Release
MGL Americas, Inc. and ProFACT Proteomics, Inc. Collaborate on Biomarker Discovery
Monmouth Junction, NJ, April 23, 2010: MGL Americas, Inc., New York, NY and ProFACT Proteomics, Inc., Monmouth Junction, NJ signed a Memorandum Of Understanding to contribute their technologies to provide solutions to industry-critical problems in Biomarker Discovery.
The MGL/ProFACT collaboration targets key challenges in translating clinically relevant data developed from the superabundance of Gene Expression research into biomarkers and ultimately, into new therapies. The near-term clinical benefits of biomarkers will be in drug trial safety and efficacy, and in developing new companion diagnostics. However, the immediate and pressing need is to distill subsets of genes most relevant to disease, and then to verify the presence or function of the gene product(s) in disease samples. This has been especially difficult because of the poor correlation between gene expression data and Mass Spec proteomic data.
To these ends, the MGL/ProFACT collaboration seeks to provide:
- Query-driven rules to prioritize the exploitation of a client-driven gene set (or panel) based on clinical goals, biological significance, costs, and detection methodologies.
- Enrichment strategies that create and exploit proteomic datasets consisting of expression, abundance and function.
- A bioinformatics knowledgebase that collects and references the most practical measureable protein attributes for a client project.
About ProFACT Proteomics, Inc.
ProFACT Proteomics, Inc. applies enabling proprietary Functional Proteomics technology to the development of therapeutics, biomarkers and personalized medicine, principally for cancer. Through collaboration and service agreements, ProFACT offers four discovery-related platforms: SeraFILE™, for reduction of protein complexity and sub-proteome creation; Rational Proteome Prospecting™, to enrich and isolate functional activity; Conformerics™, to generate drug screening assays based on enzyme sub-states or conformers; and Rational Genome to Proteome Prospecting™, to exploit gene expression data.
About Mascon Global Limited (MGL)
Mascon Global Limited (BSE: MASCONGLO) is an information, domain-centric technology solutions company, headquartered in Delhi India, with development centers worldwide. MGL delivers IT solutions across multiple industries and holds leadership positions in the worlds of finance, healthcare and life sciences, education, media and telecommunications. It is a full-spectrum service provider to the global healthcare and biopharmaceutical industry offering large-scale data management and scientific computing, specialized product engineering for life sciences, in-silico services for drug discovery and development, electronic medical records, personalized health services, and data analytics.
ProFACT Proteomics
732-230-3021
|
